Clot Risk High With Oral Contraceptives for Those at Genetic Risk
By Lori Solomon HealthDay Reporter
FRIDAY, Dec. 1, 2023 -- Oral contraceptive (OC) use is associated with an increased risk for developing a venous thromboembolism (VTE), particularly among women with a high genetic predisposition, according to a study recently published online in the American Journal of Obstetrics & Gynecology.
Valeria Lo Faro, Ph.D., from Uppsala University in Sweden, and colleagues estimated the risk for developing VTE when initiating OC use (first two years) and during continued use among women with a high genetic liability. The analysis included 244,420 participants in the U.K. Biobank.
The researchers found that overall, there was an increased risk for VTE during the first two years of OC use (hazard ratio [HR], 3.09; 95 percent confidence interval [CI], 3.00 to 3.20) but not during continued use (HR, 0.92; 95 percent CI, 0.80 to 1.05). When considering genetic risk, women in the highest polygenic risk score group had a more pronounced risk for VTE during the first two years of OC use. Similarly, high risk was seen among factor V Leiden and prothrombin variant carriers. The combination of a high polygenic risk score and being a factor V Leiden and prothrombin variant carrier conferred the highest risk for developing a VTE during the first two years of OC use (HR, 14.8; 95 percent CI, 9.28 to 23.6). During continued use, women with a high genetic liability also had increased VTE risk, but it was less pronounced.
"This is important knowledge for women’s health and may be important in contraception counselling," Lo Faro said in a statement.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Transient Increase Seen in Contraceptive Use After Dobbs Decision
MONDAY, April 15, 2024 -- A transient increase in contraceptive use was seen following the Dobbs v Jackson Women's Health Organization decision, with a return to overall downward...
Birth Rate in United States Remained Unchanged From 2021 to 2022
THURSDAY, April 4, 2024 -- The birth rate in the United States was essentially unchanged from 2021 to 2022, according to the April 4 National Vital Statistics Reports, a...
Consumers Are Most Frequent Posters of Contraception Info on Social Media
MONDAY, April 1, 2024 -- Social media is a popular conduit for birth control information, according to a study published online Feb. 7 in Contraception and Reproductive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.